Unitaid, a hosted funding partner of the WHO, announced investment in the TLC-ART drug-combination nanoparticle platform technology to transform current short-acting HIV drug combinations into long-acting medicines to simplify treatment for people living with HIV.
Category: News
Acceptability Study Results Suggest Effectiveness is the Key to Injectable HIV Treatment
Recent work by our TLC-ART team members revealed that effectiveness and frequency are the two key factors affecting patent and consumer acceptability criteria of long-acting antiretroviral therapy. Even so, effectiveness has the highest significance (p=0.0005).
Profs. Susan Graham and Jane Simoni Innovate with Patient Profile Grant
Professors Susan Graham (Global Health and Medicine) and Jane Simoni (Psychology) have recently received NIH grant support to study consumer and advocate preferences for long-acting injectable anti-retroviral therapies for HIV in both the United States (Seattle and Atlanta) and Kenya (Nairobi).
NIH Supports TLC-ART Program to Test a Novel Long-Acting Drug Combination in Humans
TLC-ART has proposed and received NIH funding to begin human testing of our 3-drug combination HIV medicines. Current long-acting HIV treatments use only one drug. TLC-ART’s goal is to transform short-acting HIV drugs into long-acting combinations that target the virus in the blood and lymphs.
Unitaid and TLC-ART Are Developing a Grant Agreement for Making Long-Acting HIV Medicines for Global Health
Unitaid, a part of the WHO, engaged the UW’s TLC-ART program for developing a grant agreement (GAD). It intends to accelerate the global impact of long-acting (LA) HIV medicines enabled by TLC-ART innovations. The project will transform current oral drugs into more effective, targeted LA therapies to improve patient appeal.
Dr. Rodney Ho Presents T-Cell Webinar to 500+ Scientists
On 8/8/2019 Dr. Rodney Ho presented a Webinar on T-Cells to an audience of over 500 to the American Chemical Society (ACS) titled “Transformation of Recombinant Cells to FDA Approved Products: Clinical Development to Marketplace.”
Rodney Ho recognized with AACP Volwiler Research Achievement Award
Dr. Rodney Ho was named recipient of the American Association of Colleges of Pharmacy (AACP) Volwiler Research Achievement Award. Rodney is the second UWSOP faculty member to receive this prestigious award. The award ceremony took place in Chicago, IL on Monday, July 15th.
Swiss Acad of Pharm Sci (SAPhS)
Prof. Borchard, President of SAPhS invited Dr. Ho to deliver a lecture at the Univ of Geneva. The presentation was entitled, “Targeted drug-combination nanoparticles for long-acting application in HIV and Cancer.”
GPEN conference; Singapore
At the 2018 GPEN 1 conference in Singapore, Dr. Rodney Ho and Jesse Yu, a graduate student presented TLC-ART research progress. Jesse’s presented his work on, “Novel drug combination matrix in solid states enabled by stable interactions of hydrophilic and hydrophobic HIV drug combination plus lipid excipients.” Dr. Ho’s held a workshop entitled, “Development and Validation of a MBPK (mechanism-based pharmacokinetic) Model to guide complex injectable drug-combination products”. Sept. 2018
1 GPEN, Globalization of Pharmaceutics Education Network (GPEN); the meeting was organized by students assisted by faculty advisers for the sole purpose of fostering and facilitating international pharmaceutical science exchange.
Luminary Award, CIE
Dr. Ho received the Luminary Innovator Award from CIE 1. He was recognized in Sept 2018 in Bellevue, WA for his innovations in science and product development. Sept. 2018
1 CIE is the Chinese Institute of Engineers. CIE Seattle promotes academic and professional excellence in the Asian Pacific American community through programs advancing innovation, collaboration and education.